Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines

Rhea-AI Summary

Vanda Pharmaceuticals (NASDAQ: VNDA) on April 9, 2026 urged FDA Commissioner Dr. Marty Makary to withdraw a FY 2027 proposal that would remove the 180‑day NDA statutory review requirement and replace it with longer PDUFA/GDUFA performance goals.

The company says the change would extend total review times to 10–12 months, eliminate formal evidentiary hearings, and roll back a recent court-ordered hearing Vanda won after more than 40 years.

Positive

• D.C. Circuit ruling compelled FDA to grant first formal drug hearing in 40+ years
• Public advocacy could influence Congress to oppose the FY 2027 proposal

Negative

• Proposal would remove 180‑day statutory NDA review requirement
• Would shift to PDUFA/GDUFA timelines producing typical 10–12 month total reviews
• Proposal replaces formal evidentiary hearings with a weaker internal appeal, reducing transparency

News Market Reaction – VNDA

+0.55%

+0.55% Session close to close

In the Apr 9 session, VNDA gained 0.55%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Vanda’s continued public challenge to FDA procedures, focusing on propo...

Analysis

This announcement highlights Vanda’s continued public challenge to FDA procedures, focusing on proposed FY 2027 changes that would replace the 180-day NDA review requirement with longer PDUFA/GDUFA timelines and weaker appeal rights. It follows recent milestones such as BYSANTI™’s FDA approval and an accepted BLA for imsidolimab, as well as litigation that secured a rare formal drug approval hearing. Investors may watch how FDA legislative negotiations evolve and how this policy backdrop intersects with Vanda’s existing product and pipeline approvals.

Key Figures

NDA statutory review timeline: 180 days Filing decision time: up to two months Total review time: 10 to 12 months +3 more

6 metrics

NDA statutory review timeline 180 days Current legal requirement for FDA new drug application review

Filing decision time up to two months Time FDA takes to decide whether to file an application under PDUFA/GDUFA goals

Total review time 10 to 12 months Typical end-to-end FDA review time from submission to decision

Formal hearing gap over 40 years Period without formal drug approval hearings before Vanda’s case

First hearing in decades more than four decades Time since last such evidentiary drug approval hearing before Vanda

Shelf registration capacity $200,000,000 Maximum aggregate offering amount under S-3 shelf filed Feb 2026

Historical Context

5 past events · Latest: Mar 19 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 19	FDA guidance critique	Negative	-16.9%	Company criticized FDA draft guidance on NAMs as lacking needed detail.
Mar 03	Drug hearing granted	Positive	-4.0%	FDA granted rare formal evidentiary hearing for HETLIOZ® jet lag sNDA.
Feb 26	Conference participation	Neutral	+3.6%	Announcement of corporate presentation at 2026 Citizens Life Sciences Conference.
Feb 25	BLA filing accepted	Positive	+1.4%	FDA accepted BLA for imsidolimab in generalized pustular psoriasis with action date.
Feb 20	Major FDA approval	Positive	+41.5%	FDA approved BYSANTI™ for bipolar I disorder and schizophrenia with long patent life.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent FDA- and policy-related headlines often produced sharp moves, with clear alignment on strongly positive approvals and a notable selloff on confrontational FDA commentary.

Recent Company History

Over the last few months, Vanda has had several major FDA touchpoints. On Feb 20, 2026, BYSANTI™ won FDA approval, with shares up 41.49%. On Feb 25, the FDA accepted a BLA for imsidolimab in GPP, and on Mar 3 the FDA granted a rare formal drug approval hearing for HETLIOZ® jet lag, though the latter saw a -4.04% reaction. More recently, Vanda publicly criticized FDA draft guidance on NAMs on Mar 19, coinciding with a -16.92% move. Today’s statement continues this pattern of public engagement with FDA policy and process.

Key Terms

new drug application (nda), prescription drug user fee act (pdufa), generic drug user fee amendments (gdufa), complete response letters, +2 more

6 terms

new drug application (nda) regulatory

"requirement that the FDA must review a new drug application (NDA) within 180 days"

A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug’s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company's stock value.

prescription drug user fee act (pdufa) regulatory

"with the longer Prescription Drug User Fee Act (PDUFA) and Generic Drug User Fee"

The Prescription Drug User Fee Act (PDUFA) is a law that allows drug companies to pay fees to the government to help speed up the review process for new medicines. This funding aims to ensure that important drugs reach patients faster, which can influence a company's ability to bring products to market efficiently. For investors, PDUFA-related decisions can impact drug approval timelines and company performance.

generic drug user fee amendments (gdufa) regulatory

"Act (PDUFA) and Generic Drug User Fee Amendments (GDUFA) performance goals."

A program under which makers of generic medicines pay fees to the regulator to fund and accelerate the review and approval of generic drug applications. Think of it like a subscription that helps the regulator hire staff and improve processes so copies of branded drugs reach pharmacies faster and with more predictable timelines. For investors, GDUFA affects approval speed, regulatory costs, market competition and revenue timing for companies making generics.

complete response letters regulatory

"exceeding the 180-day statutory timeline by issuing Complete Response Letters and"

A complete response letter is a formal communication from a drug or medical device regulator (commonly the U.S. Food and Drug Administration) telling a company that its application for marketing approval cannot be approved in its current form. It lists specific deficiencies and what must change or be provided next—like a teacher returning an exam with required corrections—and matters to investors because it delays potential product sales and can require additional time, expense or trials before the company can generate revenue from the product.

formal evidentiary hearing regulatory

"replace the formal evidentiary hearing process required by current law with a weaker"

A formal evidentiary hearing is a structured legal or regulatory session where witnesses give testimony under oath and documents or other evidence are examined before a decision-maker. Think of it like a focused courtroom meeting that records facts and arguments so authorities can decide on penalties, licenses, or rules; investors care because outcomes can change a company’s legal exposure, operating permissions, financial liabilities, and therefore its stock value.

internal streamlined appeal regulatory

"with a weaker, internal streamlined appeal."

An internal streamlined appeal is a faster, simplified process inside an organization to ask for a reconsideration of a prior decision—such as a denied claim, permit, or project approval—without resorting to outside courts or regulators. For investors it matters because this internal fast-track can shorten the time to reverse decisions that affect revenue, regulatory standing or timelines, much like using an express lane to clear a hold-up more quickly than a full external review.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WASHINGTON, April 9, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today highlighted a legislative proposal contained in the FDA's FY 2027 Congressional Budget Justification.

The proposal would eliminate the simple statutory requirement that the FDA must review a new drug application (NDA) within 180 days of filing.

In plain terms, this change would extend statutory review timelines rather than shorten them. It would replace the 180-day legal requirement with the longer Prescription Drug User Fee Act (PDUFA) and Generic Drug User Fee Amendments (GDUFA) performance goals. Under those goals, the FDA takes up to two months simply to decide whether to "file" the application. Only after that does the official review clock begin, resulting in typical total review times of 10 to 12 months from submission to decision.

The proposal would also replace the formal evidentiary hearing process required by current law with a weaker, internal streamlined appeal. The FDA has avoided providing the statutorily mandated opportunity for a formal evidentiary hearing on drug non-approvals for over 40 years, until Vanda's successful litigation forced the agency to grant the first such hearing in more than four decades.

"The FDA's current practice of exceeding the 180-day statutory timeline by issuing Complete Response Letters and operating under longer PDUFA timelines has already been ruled by federal courts to violate the law," said Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board of Vanda Pharmaceuticals.  "Instead of complying with the law as written, this proposal asks Congress to change the law so the slower system becomes legal. This is especially concerning because Commissioner Makary said just days ago that the current two-month filing review is too long and should take just days—yet this proposal seeks to codify that very delay into law. At the same time, the FDA seeks to replace the formal hearing process with a streamlined internal appeal, despite the U.S. Court of Appeals for the D.C. Circuit having ruled only months ago that the FDA unlawfully denied Vanda a proper hearing in the HETLIOZ^® jet‑lag case, and after the agency was compelled to grant Vanda the first formal drug approval hearing statutorily required but effectively avoided by the FDA for more than forty years."

Vanda supports genuine efforts to cut red tape and improve efficiency. However, this proposal does the opposite: it entrenches longer review times, reduces transparency for patients, and protects bureaucratic inertia instead of innovation. American patients would wait longer for needed medicines, while small innovators like Vanda would face greater financial risk and uncertainty.

Vanda calls on FDA Commissioner Dr. Marty Makary to withdraw this provision from the FY 2027 legislative agenda and urges Congress to reject the proposal.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

Corporate Contact:

Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com

Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com

Follow us on X @vandapharma

View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-calls-on-fda-to-withdraw-proposal-from-fy-2027-legislative-agenda-that-would-extend-drug-review-timelines-302738440.html

SOURCE Vanda Pharmaceuticals Inc.

FAQ

What is Vanda (VNDA) asking the FDA to do on April 9, 2026?

Vanda is asking FDA Commissioner Dr. Marty Makary to withdraw the FY 2027 proposal immediately. According to the company, the proposal would eliminate the 180‑day NDA requirement and extend drug review timelines to typical 10–12 months.

How would the FY 2027 proposal affect NDA review timelines for VNDA drugs?

The proposal would replace the 180‑day statutory clock with PDUFA/GDUFA goals, lengthening reviews to ~10–12 months. According to Vanda, the agency often uses two months before 'filing,' increasing total submission‑to‑decision time.

Did Vanda (VNDA) win any court rulings related to FDA hearings?

Yes. Vanda won litigation that forced the FDA to grant a formal evidentiary hearing. According to the company, this was the first such hearing the FDA granted in over 40 years after a D.C. Circuit ruling.

Why does Vanda (VNDA) say the proposal harms small innovators and patients?

Vanda says longer reviews and fewer formal hearings increase financial risk and delay patient access. According to the company, entrenching PDUFA timelines would reduce transparency and slow availability of needed medicines.

What specific legal and procedural changes does Vanda (VNDA) criticize in the proposal?

Vanda criticizes removal of the 180‑day statutory review and replacement of formal evidentiary hearings with internal appeals. According to the company, these changes would legalize longer review practices and weaken appeal rights.